Skip to main content

Table 4 CSF and serum analyses of patients with COVID-19

From: Neurological symptoms in COVID-19: a cross-sectional monocentric study of hospitalized patients

CSF parameters

Patient # of total 53 patients (see Additional file 1

(age)

Cells/μl (< 5)

Total Protein g/l (0.2–0.4)

Lactate mmol/l (1.1–2.4)

Glucose mg/dl (40–70)

Blood-brain-barrier dysfunction

Oligoclonal Bands (Isoelectric focussing)

SARS-CoV-2 PCR

2 (62)a

12

0.61

2.1

2

yes

negative

negative

20 (53)

3

0.42

2.0

85

no

negative

not available

21 (75)

1

0.18

1.4

41

no

negative

negative

23 (76)

2

0.34

1.7

55

no

negative

negative

32 (69)

10

0.95

3.5

87

yes

negative

negative

33 (59)

12

0.3

4.3

83

yes

negative

negative

37 (56)

2

0.39

2.2

80

no

negative

negative

45 (77)

2

0.31

1.5

64

no

negative

negative

53 (55)a

1

0.19

2.8

105

no

negative

negative

Specific serum analysis

Patient # (age)

D-dimers ng/ml (< 500)

Ferritin ng/ml (15–150)

Il-2-Rc U/ml (158–623)

Il-6 pg/ml (< 7.0)

TNF-alpha pg/ml (< 8.1)

NSE ng/ml (< 17)

 

2 (62)a

13,662

1497

6455

4203

74.1

26

 

20 (53)

292

232

452

22

10

n.a.

 

21 (75)

1209

234

n.a.

n.a.

n.a.

n.a.

 

23 (76)

613

415

< 158

21

6.8

n.a.

 

32 (69)

23,237

2277

943

1407

25

29

 

33 (59)

25,243

6644

4343

331

44

31

 

37 (56)

95,052

3501

2245

1408

27

51

 

45 (77)

1170

1790

1007

1369

< 8

n.a.

 

53 (55)a

24,754

5264

n.a.

636

n.a.

n.a.

 
  1. CSF Cerebrospinal fluid, Il-2-Rc Interleukin-2 receptor, Il-6 Interleukin-6, TNF-alpha Tumor necrosis factor, NSE Neuron-specific enolase, n.a. Not available
  2. apatient died during the course of the disease